Silence Therapeutics (SLN) Gross Margin (2020 - 2025)
Historic Gross Margin for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to 59.75%.
- Silence Therapeutics' Gross Margin rose 2026700.0% to 59.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.32%, marking a year-over-year increase of 470800.0%. This contributed to the annual value of 72.7% for FY2024, which is 133600.0% up from last year.
- Silence Therapeutics' Gross Margin amounted to 59.75% in Q3 2025, which was up 2026700.0% from 62.05% recorded in Q2 2025.
- Over the past 5 years, Silence Therapeutics' Gross Margin peaked at 91.95% during Q4 2024, and registered a low of 322.12% during Q2 2024.
- In the last 5 years, Silence Therapeutics' Gross Margin had a median value of 42.57% in 2023 and averaged 19.08%.
- As far as peak fluctuations go, Silence Therapeutics' Gross Margin crashed by -3910300bps in 2024, and later soared by 3841800bps in 2025.
- Silence Therapeutics' Gross Margin (Quarter) stood at 0.0% in 2021, then soared by 124738837bps to 19.01% in 2022, then soared by 89bps to 35.87% in 2023, then soared by 156bps to 91.95% in 2024, then crashed by -35bps to 59.75% in 2025.
- Its Gross Margin was 59.75% in Q3 2025, compared to 62.05% in Q2 2025 and 61.97% in Q1 2025.